November 2007 Volume 12.11

CorNotes

CVI SEMINAR SERIES

The next CVI Seminar will be held on November 15, 2007 at 4:00 pm in the Van Kampen Conference Center, Building 110, Rm 6274. Our speaker is:

David Dostal, Ph.D.
Associate Professor
Division of Molecular Cardiology
Texas A&M Health Sciences Center
Temple, TX

The title of Dr. Dostal's Seminar will be announced in a subsequent mailing.

For further information about the CVI Seminar Series and future speakers, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

November 8……Dr. Mestril
November 29……Dr. Cribbs

For further information, contact Dr. Ken Byron at x72819.

WHITE MEMORIAL FUND

Just another reminder that an endowment fund has been established to defray the cost of student travel and presentation at scientific meetings, and to support the cost of publishing scientific manuscripts by medical and graduate students. The endowment has been funded by Richard E. White and Angeline (Faye) Schrater in memory of Mr. White's parents. Faculty members who require travel support for their students to attend scientific meetings, or to defray publication costs of student papers, should direct written requests for funding to Dr. Samarel, Director of Research, CVI

CARDIOLOGY BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

November 8……Dr. Joseph Akar

The title of Dr. Akar's talk is:

"Basic Cardiac Electrophysiology"

For further information, contact Dr. Samarel at x72821

CD-EAS Clinical Trial

Dr. David Wilber, Director of the Cardiovascular Institute, is the principal investigator conducting the CF-EAS clinical trial in cooperation with CardioFocus, Inc. This is a prospective, randomized, pivotal study for the treatment of atrial fibrillation.

To this end, this study aims to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System in the treatment of atrial fibrillation by creating electrical isolation of the pulmonary veins. The Endoscopic System approach allows direct visualization of the pulmonary veins during the ablation. This technology, lazar energy and endoscopic visualization, is unique to this study. Currently, ablation is performed with radiofrequency energy and 3 dimensional anatomical mapping.

Patients are randomized to medication or ablation. If a patient fails the medication arm, they are given the choice to have the ablation using the investigational system. The patient can cross over and have the ablation. Follow-up for cross-over patients is extended to include one year post ablation. Two patients are allowed per site for training. These participants are not randomized and are not counted in the pivotal study.

For more information or to alert the Electrophysiology team of potential participants, please contact the project's coordinator, Jean DelPriore, at 708-216-2644.